Chart Industries, Inc. (NYSE:GTLS) Q1 2023 Earnings Conference Call April 28, 2023 8:30 AM ET
Company Participants
Jillian C. Evanko - President and CEO
Joseph Brinkman - CFO
Conference Call Participants
Benjamin Nolan - Stifel, Nicolaus
Eric Stine - Craig-Hallum
Martin Malloy - Johnson Rice
Pavel Molchanov - Raymond James
Sam Burwell - Jefferies
Robert Brown - Lake Street Capital Markets
Marc Bianchi - TD Cowen
Walter Liptak - Seaport Research Partners
Craig Shere - Tuohy Brothers
Barry Haimes - Sage Asset Management
Operator
Good morning and welcome to the Chart Industries, Inc. 2023 First Quarter Results Conference Call. All lines have been placed on mute to prevent background noise. After the speaker’s remarks there will be a question-and-answer session. The company’s release and supplemental presentation was issued earlier this morning. If you have not received the release, you may access it by visiting Chart's website at www.Chartindustries.com. A telephone replay of today's broadcast will be available following the conclusion of the call until Friday, May 5, 2023. The replay information is contained in the company's press release.
Before we begin, the company would like to remind you that statements made during this call that are not historical, in fact, are forward-looking statements. Please refer to the information regarding forward-looking statements and risk factors included in the company's earnings release and latest filings with the SEC. The company undertakes no obligation to update publicly or revise any forward-looking statement. I would now like to turn the conference over to Jill Evanko, Chart Industry's CEO. Please go ahead.
Jillian C. Evanko
Thank you and good morning. Thanks everybody for joining us this morning. With me today is Joe Brinkman, our CFO. We will share our strong first quarter 2023 results as well as the ahead of schedule cost and commercial synergy progress that we have made following our completion of the Howden acquisition on March 17th. There are two important data points related to the presentation we released this morning. First, all results discussed relate to continuing operations and the only discontinued operations in the quarter are related to the March 2023 settlement for the Pacific Fertility Clinic litigation matter related to our 2020 divestiture of our CryoBio business. Second, unless otherwise noted, the first quarter of 2023 results are full charge stand-alone for the quarter, plus Howden's Q1 results from our stub ownership period, which was March 17th to March 31, 2023.